Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015
Clinical Reasoning: A 28-year-old IV Drug User with Bilateral Basal Ganglia and Brainstem Lesions
Neurol 80:e73-e76, Lin, T.,et al, 2013
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis
Mod Rheumatol 17-72-74, Yamamoto, M.,et al, 2007
Bilateral Anterior Toxic Optic Neuropathy and the Use of Infliximab
BMJ 326:579, ten Tusscher,M.P.M.,et al, 2003
Toxic Leukoencephalopathy
NEJM 345:425-432, Filley,C.M. &Kleinschmidt-DeMasters,B.K., 2001
Onset of Multiple Sclerosis Associated With Anti-TNF Therapy
Neurol 57:1885-1888, Sicotte,N.L. &Voskuhl,R.R., 2001
Cerebrovascular Events After Myocardial Infarction:Analysis of the GISSI Trial
BMJ 302:1428-1431, Maggioni,A.P.,et al, 1991
Putaminal Hemorrhage:Clinical-Computed Tomographic Correlations
Neuroradiology 32:200-206, Weisberg,L.A.,et al, 1990
Neurotoxicity After Treatment with Muromonab-CD3
NEJM 323:487-488, Richards,J.M.,et al, 1990
Nosocomial Aseptic Meningitis Associated with Administration of OKT3
JAMA 259:2002-2005, Martin,M.A.,et al, 1988